Ionis Pharmaceuticals, Inc.

NasdaqGS:IONS 주식 보고서

시가총액: US$5.4b

Ionis Pharmaceuticals 관리

관리 기준 확인 2/4

Ionis Pharmaceuticals CEO는 Brett Monia, Jan2020 에 임명되었습니다 의 임기는 4.83 년입니다. 총 연간 보상은 $ 12.50M, 7.7% 로 구성됩니다. 7.7% 급여 및 92.3% 보너스(회사 주식 및 옵션 포함). 는 $ 5.69M 가치에 해당하는 회사 주식의 0.11% 직접 소유합니다. 5.69M. 경영진과 이사회의 평균 재임 기간은 각각 4.8 년과 8.5 년입니다.

주요 정보

Brett Monia

최고 경영자

US$12.5m

총 보상

CEO 급여 비율7.7%
CEO 임기4.8yrs
CEO 소유권0.1%
경영진 평균 재임 기간4.8yrs
이사회 평균 재임 기간8.5yrs

최근 관리 업데이트

Recent updates

Ionis Pharmaceuticals: Catalysts Due In 2025/2026 Are Extremely Compelling

Oct 23

There Is A Reason Ionis Pharmaceuticals, Inc.'s (NASDAQ:IONS) Price Is Undemanding

Aug 24
There Is A Reason Ionis Pharmaceuticals, Inc.'s (NASDAQ:IONS) Price Is Undemanding

Ionis Pharmaceuticals: Harnessing RNA-Targeted Therapies For Long-Term Shareholder Value

Aug 11

Health Check: How Prudently Does Ionis Pharmaceuticals (NASDAQ:IONS) Use Debt?

Jul 28
Health Check: How Prudently Does Ionis Pharmaceuticals (NASDAQ:IONS) Use Debt?

Ionis: Tough Run For Share Price Belies Multiple Reasons For Optimism

May 28

Analysts Have Made A Financial Statement On Ionis Pharmaceuticals, Inc.'s (NASDAQ:IONS) First-Quarter Report

May 09
Analysts Have Made A Financial Statement On Ionis Pharmaceuticals, Inc.'s (NASDAQ:IONS) First-Quarter Report

Lacklustre Performance Is Driving Ionis Pharmaceuticals, Inc.'s (NASDAQ:IONS) Low P/S

Apr 14
Lacklustre Performance Is Driving Ionis Pharmaceuticals, Inc.'s (NASDAQ:IONS) Low P/S

Is Ionis Pharmaceuticals (NASDAQ:IONS) Using Debt Sensibly?

Mar 18
Is Ionis Pharmaceuticals (NASDAQ:IONS) Using Debt Sensibly?

Ionis Pharmaceuticals 2023 Earnings Review: Short-Term Pain, Long-Term Gain

Feb 23

Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) Investors Are Less Pessimistic Than Expected

Dec 28
Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) Investors Are Less Pessimistic Than Expected

Ionis Pharmaceuticals (NASDAQ:IONS) Has Debt But No Earnings; Should You Worry?

Dec 07
Ionis Pharmaceuticals (NASDAQ:IONS) Has Debt But No Earnings; Should You Worry?

A Look At The Intrinsic Value Of Ionis Pharmaceuticals, Inc. (NASDAQ:IONS)

Nov 16
A Look At The Intrinsic Value Of Ionis Pharmaceuticals, Inc. (NASDAQ:IONS)

Ionis Pharmaceuticals (NASDAQ:IONS) Has Debt But No Earnings; Should You Worry?

Aug 03
Ionis Pharmaceuticals (NASDAQ:IONS) Has Debt But No Earnings; Should You Worry?

Is Ionis Pharmaceuticals (NASDAQ:IONS) Using Debt Sensibly?

May 05
Is Ionis Pharmaceuticals (NASDAQ:IONS) Using Debt Sensibly?

Does Ionis Pharmaceuticals (NASDAQ:IONS) Have A Healthy Balance Sheet?

Jan 20
Does Ionis Pharmaceuticals (NASDAQ:IONS) Have A Healthy Balance Sheet?

Ionis Pharmaceuticals Looks Good For The Long Term

Oct 19

Ionis plans for new manufacturing site in California to support pipeline

Oct 13

Ionis: 2 Drug Advancements With Potential Firsts

Aug 29

Ionis Pharmaceuticals Q2 2022 Earnings Preview

Aug 08

CEO 보상 분석

Brett Monia 의 보수는 Ionis Pharmaceuticals 의 수익과 비교하여 어떻게 변경되었나요?
날짜총 보상급여회사 수익
Sep 30 2024n/an/a

-US$359m

Jun 30 2024n/an/a

-US$366m

Mar 31 2024n/an/a

-US$385m

Dec 31 2023US$13mUS$961k

-US$366m

Sep 30 2023n/an/a

-US$409m

Jun 30 2023n/an/a

-US$309m

Mar 31 2023n/an/a

-US$329m

Dec 31 2022US$7mUS$825k

-US$270m

Sep 30 2022n/an/a

US$7m

Jun 30 2022n/an/a

-US$28m

Mar 31 2022n/an/a

-US$4m

Dec 31 2021US$13mUS$800k

-US$29m

Sep 30 2021n/an/a

-US$608m

Jun 30 2021n/an/a

-US$550m

Mar 31 2021n/an/a

-US$495m

Dec 31 2020US$11mUS$700k

-US$444m

Sep 30 2020n/an/a

US$94m

Jun 30 2020n/an/a

US$145m

Mar 31 2020n/an/a

US$169m

Dec 31 2019US$7mUS$528k

US$281m

Sep 30 2019n/an/a

US$433m

Jun 30 2019n/an/a

US$402m

Mar 31 2019n/an/a

US$366m

Dec 31 2018US$4mUS$508k

US$277m

Sep 30 2018n/an/a

-US$41m

Jun 30 2018n/an/a

-US$38m

Mar 31 2018n/an/a

US$9m

Dec 31 2017US$2mUS$443k

US$19m

보상 대 시장: Brett 의 총 보상 ($USD 12.50M )은 US 시장( $USD 7.74M ).

보상과 수익: 회사가 수익성이 없는 동안 Brett 의 보상이 증가했습니다.

CEO

Brett Monia (63 yo)

4.8yrs

테뉴어

US$12,500,023

보상

Dr. Brett P. Monia, Ph.D. is a Founder of Ionis Pharmaceuticals, Inc. in 1989 and has been Chief Executive Officer since January 2020. He has extensive experience across a range of therapeutic areas, inclu...

리더십 팀

이름위치테뉴어보상소유권
Brett Monia
Founder4.8yrsUS$12.50m0.11%
$ 5.7m
Elizabeth Hougen
Executive VP of Finance & CFO11.8yrsUS$2.89m0.059%
$ 3.2m
B. Parshall
Director6.8yrsUS$538.04k0.055%
$ 3.0m
Richard Geary
Executive VP & Chief Development Officer16.3yrsUS$2.56m0.054%
$ 2.9m
Eric Swayze
Executive Vice President of Research4.8yrsUS$2.56m0.021%
$ 1.2m
Darren Gonzales
Chief Accounting Officer & Senior VP4.8yrs데이터 없음데이터 없음
C. Bennett
Executive VP & Chief Scientific Officer4.8yrsUS$958.87k0.050%
$ 2.7m
D. Walke
Senior Vice President of Investor Relationsno data데이터 없음데이터 없음
Patrick O'Neil
Executive VP11.8yrsUS$3.92m0.031%
$ 1.7m
Hayley Soffer
Vice President of Corporate Communicationsless than a year데이터 없음데이터 없음
Shannon Devers
Senior Vice President of Human Resources4.8yrs데이터 없음0.0050%
$ 269.0k
Stanley Crooke
Scientific Advisor3.4yrsUS$2.28m데이터 없음

4.8yrs

평균 재임 기간

64.5yo

평균 연령

경험이 풍부한 관리: IONS 의 관리팀은 경험 ( 4.8 년 평균 재직 기간)으로 간주됩니다.

이사회 구성원

이름위치테뉴어보상소유권
Brett Monia
Founder5.7yrsUS$12.50m0.11%
$ 5.7m
B. Parshall
Director24.2yrsUS$538.04k0.055%
$ 3.0m
Joan Herman
Independent Director5.4yrsUS$540.04k0.027%
$ 1.4m
Joseph Klein
Independent Director18.9yrsUS$542.04k0.010%
$ 559.6k
Joseph Wender
Lead Independent Director30.8yrsUS$598.04k0.084%
$ 4.5m
Michael Hayden
Independent Director6.2yrsUS$528.04k0.020%
$ 1.1m
Spencer Berthelsen
Independent Director22.5yrsUS$548.04k0.096%
$ 5.2m
Joseph Loscalzo
Independent Chairman of the Board10.8yrsUS$568.04k0.020%
$ 1.1m
Allene Diaz
Independent Director3.4yrsUS$530.04k0.010%
$ 534.3k
Michael Yang
Independent Directorless than a yearUS$363.05k데이터 없음

8.5yrs

평균 재임 기간

70yo

평균 연령

경험이 풍부한 이사회: IONS 의 이사회는 경험(평균 재직 기간 8.5 년)으로 간주됩니다.